<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336641">
  <stage>Registered</stage>
  <submitdate>7/03/2011</submitdate>
  <approvaldate>7/03/2011</approvaldate>
  <actrnumber>ACTRN12611000249954</actrnumber>
  <trial_identification>
    <studytitle>The Fenofibrate And Microvascular Event Eye (FAME 1 EYE) Trial in Adults with Type 1 Diabetes Mellitus: A randomised trial in adults with type 1 diabetes mellitus evaluating the effects of daily oral fenofibrate compared with placebo on macular thickness and volume</studytitle>
    <scientifictitle>A randomised trial in adults with type 1 diabetes mellitus evaluating the effects of daily oral fenofibrate compared with placebo on macular thickness and volume</scientifictitle>
    <utrn />
    <trialacronym>The FAME 1 EYE Trial</trialacronym>
    <secondaryid>N/A</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Eye disease (retinopathy) in type 1 diabetes mellitus</healthcondition>
    <healthcondition>Diabetic nephropathy in type 1 diabetes mellitus</healthcondition>
    <conditioncode>
      <conditioncode1>Eye</conditioncode1>
      <conditioncode2>Diseases / disorders of the eye</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Oral Fenofibrate 145mg given once daily for 12 months.</interventions>
    <comparator>Oral matching inert lactose placebo once daily for 12 months.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Central zone macular thickness measured using optical coherence tomography</outcome>
      <timepoint>At 12 months after randomisation</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Total macular volume measured using optical coherence tomography.</outcome>
      <timepoint>At 12 months after randomisation</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Aluminuria measured as urinary albumin:creatinine ratio.</outcome>
      <timepoint>Assessed at 12 months after randomisation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Visual acuity using Snellen Chart</outcome>
      <timepoint>At 12 months after randomisation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Corneal confocal microscopic measurement of neural damage (only assessed in a representative subset of the participants at sites with the specialised confocal microscope).</outcome>
      <timepoint>At 12 months after randomisation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Estimated glomerular filtration rate using MDRD formula</outcome>
      <timepoint>At 12 months after randomisation.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Peripheral neuropathy status assessed by temperature sensation and monofilament sensation.</outcome>
      <timepoint>At 12 months after randomisation.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Vascular function using non-invasive pulse wave techniques and plethysmography.</outcome>
      <timepoint>At 12 months after randomisation.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Blood lipids and biomarkers in plasma</outcome>
      <timepoint>At 6 weeks, 6 months and 12 months after randomisation</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Subjects with type 1 diabetes mellitus, over 18 years of age, with established macular thickening on optical coherence tomography (OCT) greater than or equal to 300 micrometres in at least one macular zone will be eligible for inclusion in the FAME 1 Eye study. They must have no definite indication for receiving, and no contraindication to receiving fenofibrate in addition to their existing therapy.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Subjects with type 1 diabetes mellitus and the contraindications of definite need for intra-ocular treatment or photocoagulation therapy within next 3 months, allergy to any fibrate drugs, history of pancreatitis or pulmonary embolism or DVT, use of any other investigational agents in last 8 weeks, unstable condition including recent MI, heart failure, or prior organ transplant, or severe renal or liver dysfunction, or history of myositis or untreated hypothyroidism.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomisation double blinded placebo control by phone/fax/computer.</concealment>
    <sequence>Dynamic balanced randomisation.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/09/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>300</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Anthony Keech</primarysponsorname>
    <primarysponsoraddress>University of Sydney. 92-94 Parramatta Road, Camperdown.  NSW.  2050.</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Abbott Pharmaceuticals</fundingname>
      <fundingaddress>32-34 Lord Street, Botany.  NSW.  2019.</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Alicia Jenkins</othercollaboratorname>
      <othercollaboratoraddress>University of Melbourne.  Department of Medicine, St Vincents Hospital.  Regent Street, Fitzroy.  VIC. 3065.</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Peter Colman</othercollaboratorname>
      <othercollaboratoraddress>Department of Endocrinology, Royal Melbourne Hospital.  Royal Parade, Parkville, Melbourne.  VIC.</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Stephen Twigg</othercollaboratorname>
      <othercollaboratoraddress>Diabetes Unit, Royal Prince Alfred Hospital.  Missendon Road.  Camperdown.  NSW.</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>James Best</othercollaboratorname>
      <othercollaboratoraddress>Faculty of Medicine, Dentistry and Health Sciences.  University of Melbourne.  Grattan Street, Parkville, Melbourne.  VIC.</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>David O'Neal</othercollaboratorname>
      <othercollaboratoraddress>University of Melbourne.  Department of Medicine, St Vincents Hospital.  Regent Street, Fitzroy.  VIC. 3065.</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Tien Wong</othercollaboratorname>
      <othercollaboratoraddress>Centre for Eye Research Australia.  Royal Victorian Eye and Ear Hospital.  Victoria Parade.  Fitzroy.  VIC.  3065.</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Diabetes is the commonest cause of adult onset blindness.  Vision loss, which is irreversible, is a most feared complication of diabetes. A blood fat lowering drug called fenofibrate, available in Australia, has been shown to reduce eye damage in people with Type 2 diabetes by 35-40%, and to prevent eye damage in Type 1 diabetic animal models. This study will evaluate the potential benefits of fenofibrate in 300 adults with Type 1 diabetes who are at high risk of eye damage.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname />
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>1/05/2011</ethicsubmitdate>
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Anthony Keech</name>
      <address>92 - 94 Parramatta Road, Camperdown.  NSW.  2050.</address>
      <phone>+61 2 95625003</phone>
      <fax />
      <email>tony@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Anthony Keech</name>
      <address>92 - 94 Parramatta Road, Camperdown.  NSW.  2050.</address>
      <phone>+61 2 95625003</phone>
      <fax />
      <email>tony@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>